Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Change in Account Payables: 2023-2025

Historic Change in Account Payables for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to -$2.0 million.

  • Zenas BioPharma's Change in Account Payables fell 157.61% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.7 million, marking a year-over-year decrease of 160.79%. This contributed to the annual value of $11.7 million for FY2024, which is 2908.61% up from last year.
  • Zenas BioPharma's Change in Account Payables amounted to -$2.0 million in Q3 2025, which was up 83.83% from -$12.1 million recorded in Q2 2025.
  • Over the past 5 years, Zenas BioPharma's Change in Account Payables peaked at $5.4 million during Q4 2024, and registered a low of -$12.1 million during Q2 2025.
  • Its 3-year average for Change in Account Payables is $462,625, with a median of $3.0 million in 2023.
  • In the last 5 years, Zenas BioPharma's Change in Account Payables spiked by 73.75% in 2024 and then slumped by 2,418.12% in 2025.
  • Zenas BioPharma's Change in Account Payables (Quarterly) stood at $3.1 million in 2023, then soared by 73.75% to $5.4 million in 2024, then tumbled by 157.61% to -$2.0 million in 2025.
  • Its last three reported values are -$2.0 million in Q3 2025, -$12.1 million for Q2 2025, and $2.9 million during Q1 2025.